Lee Seung Jae, Oh Byeong Kil, Sung Ki-Chul
Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181 Republic of Korea.
Clin Hypertens. 2020 Jun 15;26:13. doi: 10.1186/s40885-020-00146-y. eCollection 2020.
Hyperuricemia, which has been considered as a cause of gout and nephrolithiasis has recently been suggested to be associated with hypertension, coronary heart disease, heart failure, atrial fibrillation, insulin resistance, and nonalcoholic fatty liver disease. Several clinical and experimental studies have supported uric acid (UA) as an independent risk factor for predicting disease development along with the traditional risk factors. The mechanism by which UA causes cardiometabolic disease has not been fully elucidated to date; however, it has been explained by several hypotheses such as oxidative stress, reduced nitric oxide bioavailability, inflammation, endothelial dysfunction, and so on. Although evidence of the preventive and therapeutic effects of UA lowering therapy on cardiometabolic diseases is still insufficient, it is expected to be considered as a new treatment strategy for such diseases through additional, carefully designed, large-scale clinical studies.
高尿酸血症一直被认为是痛风和肾结石的病因，最近有人提出它与高血压、冠心病、心力衰竭、心房颤动、胰岛素抵抗和非酒精性脂肪性肝病有关。多项临床和实验研究支持尿酸（UA）作为一种独立的危险因素，与传统危险因素一起可预测疾病的发展。迄今为止，UA导致心脏代谢疾病的机制尚未完全阐明；然而，已经有几种假说对此进行了解释，如氧化应激、一氧化氮生物利用度降低、炎症、内皮功能障碍等。尽管降低UA治疗对心脏代谢疾病的预防和治疗作用的证据仍然不足，但预计通过进一步精心设计的大规模临床研究，它将被视为这类疾病的一种新的治疗策略。
